Myeloproliferative Neoplasms

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera

By

Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

By

A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

By

A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

By

Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

By

A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

By

Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

By

NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.

New Predisposition Genes for Familial Polycythemia Vera Are Identified

New Predisposition Genes for Familial Polycythemia Vera Are Identified

By

Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

By

Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)

This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

By

A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.

Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New Insights

Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New Insights

By

Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

By

Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

By

In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.

Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera

Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera

By

Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.

Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.

Polycythemia Vera (Fact Sheet)

Polycythemia Vera (Fact Sheet)

This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.

Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome

Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome

By

The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.

Patients With MPNs, Physicians View Treatment Goals Differently

Patients With MPNs, Physicians View Treatment Goals Differently

By

Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

By

Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs